Drugs / CSF470
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01729663 | Apr 2009 → Dec 2018 | cutaneous melanoma | Laboratorio Pablo Cassará S.R.L. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSF-470 | “The allogeneic therapeutic vaccine CSF-470 has demonstrated a significant benefit over medium-dose IFNα2b in the distant metastasis-free survival for stages IIB-IIC-III...” PMID 29774030 ↗ May 2018 |
| Modality | Vaccine | “cellular CSF-470 vaccine” PMID 28620382 ↗ May 2017 |
| Route | Other | “1.6 × 107 irradiated CSF-470 cells plus 106 colony-forming units BCG plus 100 µg rhGM-CSF were administered intradermally” PMID 28620382 ↗ May 2017 |